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Abstract
The purpose of this study was to analyze and compare antimicrobial resistance in Campylobacter spp. isolated
from pork and poultry carcasses, and pork and poultry meat (at slaughterhouse level, during meat cutting, and
at retail) in Belgium, using available surveillance data over the period 2004–2009. The susceptibilities of 1724
Campylobacter isolates for ampicillin, ciprofloxacin, nalidixic acid, tetracycline, erythromycin, and gentamicin
were tested by E-test. Gentamicin resistance was low (near 0%) until 2007, with an increase to over 20% by 2009
for all species-matrix combinations. Resistance to tetracycline fluctuated around the same level during the entire
study period and was significantly higher ( p-value of < 0.05) in C. coli than in C. jejuni. Erythromycin resistance
was low and showed a slight decrease between 2004 and 2007, but increased from 2007 until 2009. Fluoro-
quinolone and ampicillin resistance was significantly higher in isolates derived from poultry, compared to pork-
related isolates. This correlates with the higher use of these antimicrobials in poultry husbandry. A total of 25%
of C. coli isolates from poultry showed the most apparent multiresistance (resistance to four or more antimi-
crobials). Approximately 1% of the poultry-derived isolates (both C. coli and C. jejuni) showed resistance to all
tested antimicrobials, while none was found in pork products.
Introduction
Campylobacter is the most common cause of bacterialgastroenteritis worldwide, most frequently caused by
C. jejuni, followed by C. coli and C. lari (ESFA, 2009). Since
2005, campylobacteriosis has been the most reported zoonotic
infection in Belgium, with 5635 laboratory-confirmed cases in
2009 (53 per 100,000 inhabitants), although since 2000 the
number of Campylobacter infections has shown a significant
decreasing trend at the national and regional levels (Belgian
Working Group, 2010). Although campylobacteriosis is often
self-limiting, antibiotic treatment may be necessary in severe
cases (Molbak, 2005). The treatment of choice had tradition-
ally been macrolides or fluoroquinolones, for which Campy-
lobacter spp. were historically susceptible. However, increased
resistance to both groups of antimicrobials has been observed
(Belanger and Shryock, 2007; Luangtongkum et al., 2009). In
addition, drug-resistant foodborne bacteria have a selective
advantage in patients already treated with antimicrobial
drugs for other reasons, resulting in increased transmission
(Perron et al., 2008). Also, the genes encoding for antimicrobial
drug resistance are often located on mobile genetic elements,
such as plasmids, transposons, and integrons, which can be
horizontally transferred to other bacteria, possibly pathogens
(Avrain et al., 2004; Jeon et al., 2008). It has been shown that
drug-resistant bacteria show increased virulence, causing a
longer duration of illness (Nelson et al., 2004).
Due to the zoonotic nature of campylobacteriosis, the in-
tensive use of antimicrobial agents for therapy, prophylaxis,
or growth promoters in food animal production (although the
latter has been prohibited in Europe since 2006) can contribute
considerably to increased resistance in clinical Campylobacter
isolates (EFSA, 2009, 2010; Aerestrup and Wegener, 1999).
Several European countries have monitoring programs to
assess and mitigate the risk related to antimicrobial resistance
(Ammon and Makela, 2010). The main mode of transmission
is the consumption of undercooked meat or contamination by
the food handler of fresh poultry and pork meat (Corry and
Atabay, 2001; Altekruse and Tollefson, 2003; Cools et al.,
2005). Since 2000, the contamination of pork and poultry
carcasses and meat with Campylobacter spp. has been moni-
tored in Belgium. The proportion of positive poultry samples
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shows strong annual fluctuations but overall remains high
(Table 1) (Trends and Sources, 2004–2009). Since 2004, these
strains have been tested for antimicrobial resistance. Belgium
does not yet have a central detailed surveillance system in
place on each level of antimicrobial consumption or antimi-
crobial resistance, in contrast to some other European coun-
tries such as Denmark and Sweden. These countries annually
publish detailed reports on the general use of antimicrobials
and occurrence of antimicrobial resistance in food animals,
foods, and humans. Recent efforts have been made by the
European Medicines Agency (EMA, 2009) to develop a central
database on the use of antimicrobial agents in animals (i.e.,
European Surveillance of Veterinary Antimicrobial Con-
sumption [ESVAC]). Belgium is also working on a program
for surveillance of antimicrobial use in agriculture; however,
linking and explaining different observed trends in antimi-
crobial use and resistance development remains difficult.
The aim of the present study is to analyze and compare
antimicrobial resistance proportions in Campylobacter spp.
isolated from food samples (i.e., pork and poultry carcasses
and meat) from Belgium through surveillance data over the
period 2004–2009. Six antimicrobials were tested, including
those that are recommended for therapy. Focus was placed on
detection of reduced susceptibility using European Commit-
tee on Antimicrobial Susceptibility Testing (EUCAST) epide-
miological cut-off values.
Methods
Sampling and isolation of Campylobacter isolates
Samples of pork and poultry carcasses, meat, and meat
products were taken by inspectors of the Belgian Federal
Agency for the Safety of the Food Chain (FASFC) as part of
continuous surveillance plans, as laid down in Belgian or
European Legislation. Sampling was done at random at the
level of production (i.e., at the slaughterhouse directly after
slaughter, during meat cutting, and at retail). Samples were
kept at 4C until analysis. Food stuffs sampled were pork
carcasses, broilers, spent hens, turkey carcasses, poultry parts,
poultry meat preparations, and minced poultry meat.
Campylobacter isolates from food were obtained as described
by ISO 10272-1 and 10272-2 (ISO, 2006). After isolation, the
strains were sent to the national reference laboratory of Cam-
pylobacter at the Institute of Public Health (Brussels, Belgium).
Identification of species
DNA was extracted through heat lysis (Englen and Kelley,
2000). One colony was suspended in 100lL of MQ water,
boiled for 17 min, and chilled immediately. Three different
polymerase chain reaction (PCR) protocols were utilized to
confirm all isolates as belonging to the Campylobacter genus
(Denis et al., 2001) and to identify the isolates as C. jejuni or
C. coli by molecular weight (Debruyne et al., 2008; Denis et al.,
1999; Linton et al., 1997). Primers are listed in Table 2.
Minimal inhibitory concentration (MIC) determination
Since the E-test has been found to compare favorably with
agar dilution methods (Luber et al., 2003; Oncul et al., 2003), this
test was chosen for its ease of use in the routine testing of single
isolates. Confirmed Campylobacter isolates were subcultured on
Colombia agar with 5% sheep blood (Oxoid Ltd., Hampshire,
UK) for 24 h at 42C under micro-aerophilic conditions, using
sealed boxes with gas-generating packets (Biome´rieux, Lyon,
France). MIC were determined using the E-test strips (Bio-
me´rieux), as described by the manufacturer. In short, inoculates
were adjusted to the turbidity of a 0.5 MacFarland standard
and plated on Mueller-Hinton agar supplemented with 5%
sheep blood (BioRad, Hercules, CA). Metric antimicrobial
strips were applied, two per plate, in opposite direction. Tested
antimicrobials were ampicillin (Amp), tetracycline (Tet), nali-
dixic acid (Nal), erythromycin (Ery), gentamycin (Gen) (all
0.016–256lg/mL), and ciprofloxacin (Cip; 0.002–32lg/mL).
Plates were incubated for 48 h at 37C. C. jejuni American Type
Culture Collection (ATCC) 33560 was used as control strain,
and was included in each batch during E-test.
The MIC was defined as the lowest concentration of an
antimicrobial agent that completely inhibited visible growth
Table 1. Percentage of Campylobacter-Positive Samples in Belgium
Matrix 2004 2005 2006 2007 2008 2009
Poultry carcass at slaughterhousea 27.9 (n = 197) 19.6 (n = 270) 19.0 (n = 315) 22.5 (n = 235) 33.0 (n = 185 32.0 (n = 261)
Poultry meat at processinga 26.0 (n = 131) 22.9 (n = 249) 12.4 (n = 326) 9.3 (n = 257) 7.3 (n = 523) 8.6 (n = 513)
Poultry carcass at retailb 35.0 (n = 77) 3.9 (n = 77) 42.5 (n = 40) 19.4 (n = 144) 19.1 (n = 115) 25.4 (n = 118)
Pork carcass at slaughterhousec 5.0 (n = 344) 7.2 (n = 433) 13.4 (n = 418) 12.2 (n = 213) 16.6 (n = 500) 14.0 (n = 656)
aSample size of 1 g.
bSample size of 0.01 g.
cSample size of 600 cm2.
Table 2. Primers
Primer Sequence
23SrRNA_Fa TTAGCTAATGTTGCCCGTACCG
23SrRNA_Ra AGCCAACCTTTGTAAGCCTCCG
Ery2075_Ra TAGTAAAGGTCCACGGGGTCGC
Ery2074_Ra AGTAAAGGTCCACGGGGTCTGG
Ery2074-2075_WT_Ra TAGTAAAGGTCCACGGGGTCTTT
Campjej_gyrA1_Fb TTTTTAGCAAAGATTCTGAT
Campjej_gyrA5_Rb CAAAGCATCATAAACTGCAA
Campjej_gyr_WT_Fb CAAAGCATCATAAACTGCAG
Campcol_gyr_Fb CACTTCCTGACGCTAGAGAT
Campcol_gyr_Rb TAAGGCATCGTAAACAGCCA
Campcol_gyr_WT_Rb TAAGGCATCGTAAACAGCCG
MD16S1c ATCTAATGGCTTAACCATTAAAC
MD16S2c GGACGGTAACTAGTTTAGTATT
MDmapA1c CTATTTTATTTTTGAGTGCTTGTG
MDmapA2c GCTTTATTTGCCATTTGTTTTATTA
Col3c AATTGAAAATTGCTCCAACTATG
MDcol2c TGATTTTATTATTTGTAGCAGCG
aAlonso et al. (2005).
bZirnstein et al. (1999, 2000).
cDenis et al. (1999, 2001).
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and was read at the point where the elliptical zone of inhibi-
tion intersected the MIC scale on the strip. Different measures
were used to study resistance. EUCAST epidemiological cut-
off values were used as the most sensitive measure of resis-
tance development; different cut-off values are defined for
C. coli (Amp > 8, Tet > 2, Nal > 32, Ery > 16, Gen > 2, Cip > 1)
and C. jejuni (Amp > 8, Tet > 2, Nal > 16, Ery > 4, Gen > 1, Cip
> 1). Multi-resistance was defined as simultaneous resistance
to at least four antimicrobials tested.
Mutation analysis
The gyrA C257T mutation and 23S rRNA A2074C and
A2075G mutations were examined by Mismatch Amplifica-
tion Mutation Assay (MAMA) as described by Zirnstein et al.
(1999, 2000) and Alonso et al. (2005), respectively. Primers are
listed in Table 2. Resistant strains showing no mutations by
MAMA were verified by sequence analysis, using Big Dye
Terminator mix (Applied Biosystems, Carlsbad, CA) and
analyzed on an ABI 3130 genetic analyzer.
Statistical analysis
Significance of differences between proportions of resistant
isolates were evaluated using a v2-test with Yates continuity
correction for large sampling groups (N > 20), whereas the
two-tailed Fisher exact test was used for small sampling
groups (N < 20). The 5% significance level was used ( p-
value < 0.05) for all statistical analyses.
Results and Discussion
A 6-year surveillance of randomly sampled Belgian pork and
poultry meat products at the level of slaughterhouse, proces-
sing, and retail resulted in 1724 Campylobacter isolates. This
isolate collection encompassed C. jejuni (n= 1096) and C. coli
(n= 377) from poultry carcasses and meat, and C. coli (n= 251)
from pork carcasses. Trends per species, per food matrix, per
antimicrobial, and per year were analyzed. It should be men-
tioned that it is difficult to compare results with data from other
countries due to the unavailability of comparable data. With
the exception of Denmark, other European countries only
started reporting Campylobacter antimicrobial resistance data
from meat since 2006–2007 (EFSA, 2010). Furthermore there is a
2-year time lag of the European data analysis.
Resistance trends per antimicrobial
Yearly trends in resistance per antibiotic are shown in
Figure 1. Ampicillin resistance fluctuated around the same
resistance levels for all three species-matrix combinations,
with an average resistance proportion of 13.1% and 30.8% for
C. coli from pork and poultry meat, respectively, and 37.4% for
C. jejuni from poultry meat. Tetracycline resistance showed
yearly fluctuations around the same level for all three species-
matrix combinations, with a significantly higher average
resistance ( p-value < 0.05) for C. coli (76.9% and 84.1% for
isolates from poultry and pork meat, respectively) compared
to C. jejuni (average resistance proportion of 40.8%).
Gentamicin resistance showed a significant increase between
2007 and 2009 for all three species-matrix combinations, from 0%
in 2007, to over 20% in 2009. The most recent surveillance data
from the European summary report does not show this high
gentamicin resistance among C. jejuni from broiler meat (EFSA,
2010). None of the member states reported any gentamicin re-
sistant isolates from broiler meat (EFSA, 2010). The observed
increase of resistance against aminoglycoside antibiotics (like
gentamicin) in all species-matrix combinations highlights the
potential risk on further spread of the resistance among human
pathogens. Since the introduction of the aminoglycoside apra-
mycin for agricultural use (early 1980s), resistance to apramycin
has emerged among Escherichia coli isolates found in cattle and
pigs in France and the United Kingdom (Chaslus-Dancla and
Lafont, 1985; Wray et al., 1986). The aminoglycoside 3-N-acetyl-
transferase type IV resistance gene (AAC(3)IV) and 1-N-acetyl-
transferase (AAC(1)) confer resistance to several aminoglycoside
antimicrobials (apramycin, tobramycin, gentamicin, kanamycin,
and neomycin) and were first observed in animal isolates after
the introduction of apramycin usage (Hedges and Shannon,
1986). Although apramycin has never been used for the treat-
ment of infections in humans, these resistance determinants were
subsequently found in human clinical isolates of E. coli, Salmo-
nella enterica, Klebsiella pneumoniae, and Campylobacter spp.
(Johnson et al., 1994; Gomez-Lus et al., 1999). This indicates that
the usage of apramycin in agriculture primarily selected for the
emergence of the aminoglycoside resistance genes among food
animals, which then spread horizontally to human pathogens,
where gentamicin is used for treatment.
Trends in resistance to erythromycin of all three species-
matrix combinations were stable or decreased from 2004 to
2007, but increased in 2008 and 2009 to a resistance proportion
of near 20.0% for C. coli and 12.1% for C. jejuni. Looking at the
(fluoro)quinolone resistance proportions, the yearly trends for
both Campylobacter species and both matrices were similar for
both ciprofloxacin and nalidixic acid. Resistance in C. jejuni
from poultry meat andC. coli from pork fluctuated around 40%
for the whole study period. C. coli from poultry meat showed a
consistently higher resistance for both antimicrobials, fluctu-
ating around 60% for 2004–2007, peaking in 2008 (81.4% Cip
and 86.0% Nal), and slightly decreasing in 2009. Belgian C.
jejuni fluoroquinolone resistance proportions were signifi-
cantly higher ( p-value< 0.05) than reported in poultry meat in
Denmark (19% fluoroquinolone resistance), yet similar to
poultry meat imported in Denmark (53% fluoroquinolone re-
sistance), yet lower than observed in poultry meat from Austria
and Latvia (65% and 100% fluoroquinolone resistance, re-
spectively) (DANMAP, 2008; EFSA, 2010). The observed trends
of resistance proportions for all antimicrobials, specifically the
distinct peaks for 2008, could result from changes in thera-
peutic use of these antimicrobials in animal food production
during 2008–2009. Unfortunately, this hypothesis cannot be
corroborated since detailed surveillance data of antimicrobial
use in Belgian agriculture are not yet available.
Although antimicrobial resistance was monitored as ac-
quired reduced susceptibility (using EUCAST epidemiologi-
cal cut-off values), which cannot be used to deduce clinical
implications, these observed high resistance proportions
could have important human health consequences as eryth-
romycin and ciprofloxacin are the preferred treatment for di-
agnosed cases of campylobacteriosis (Belanger and Shryock,
2007). In addition, most diarrheic patients that seek medical
attention—and are not diagnosed with campylobacteriosis—
are empirically treated with a broad-spectrum antimicrobial
(Belanger and Shryock, 2007), most frequently with fluor-
oquinolones (Engberg et al., 2004), for which especially C. coli
from poultry meat shows a high proportion of resistance.
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Resistance trends per species and matrix
Average resistance per species and matrices were calcu-
lated for the whole study period based on MIC distribution
(Table 3). In general, resistance proportions of C. coli and
C. jejuni to the tested antimicrobials from poultry meat are in
agreement with the average European results per year, which
were based on the results of only a few member states (five for
C. jejuni and three for C. coli) and to which Belgium contrib-
uted antimicrobial resistance results of 2006-2009. In Belgium
during the study period 2004-2009 comparison of the two
monitored meat matrices revealed significantly higher aver-
age resistance proportion (p-value < 0.05) to tetracycline
(84.1% for pork and 76.9% for poultry) and erythromycin
(17.9% for pork and 13.0% for poultry) for C. coli than C. jejuni
(40.8% and 6.0% respectively). Significant differences in re-
sistance proportion between matrices was not observed, ex-
cept for ciprofloxacin and nalidixic acid, for which C. coli
isolates from poultry showed higher resistance proportion
(69.5% and 69.8% respectively) compared to C. coli from pork
(both 35.5%). Furthermore, significantly higher resistance to
ampicillin was observed in poultry isolates (30.8% for C. coli
and 37.4% for C. jejuni), compared to pork isolates (13.1% for
C. coli). Although detailed surveillance data on antimicrobial
use in agriculture in Belgium are not available, some reports
show trends which could explain the observed difference of
fluoroquinolone resistance between pork and poultry food
matrices. A study conducted by Timmerman et al. (2006) on
the antimicrobial drug consumption at 821 Belgian pig herds
revealed that nearly no fluoroquinolones are used in pig
husbandry (TIUDD < 0.1, with TIUDD being the treatment in-
cidence based on the Used Daily Dose or the number of pigs
treated/1000 pigs at risk/day). The antimicrobial use in Bel-
gian broiler production shows significant use of fluor-
oquinolones (enrofloxacin, TIUDD = 6.1; flumequine,
TIUDD = 1.39) (Persoons and Dewulf, 2010). These data are
consistent with results from monitoring programs on anti-
microbial use of Denmark and The Netherlands (DANMAP,
2008; MARAN, 2007). Similarly, the use of b-lactam antimi-
crobials is higher in poultry- than in pig-husbandry (TIUDD
37.9 and 28.9, respectively) (Persoons and Dewulf, 2010;
Timmerman et al., 2006).
FIG. 1. Yearly trends of resistance to ampicillin, ciprofloxacin, nalidixic acid, tetracycline, gentamicin, and erythromycin for
Campylobacter coli isolated from pork, and C. coli and C. jejuni from poultry. The epidemiological cutoff values as stated in the
text were used.
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Multiresistance
Multiresistance (defined as resistance to four or more of the
monitored antimicrobials) of the tested Campylobacter isolates
is shown in Figure 2. Multiresistance of C. coli from poultry
was on average high (27.6%), but showed strong fluctuations
during the monitoring period. C. coli from pork and C. jejuni
from poultry showed significantly less multiresistance, with
less variation (11.2% and 15.8%, respectively). For both C. coli
and C. jejuni from poultry, isolates resistant to all tested
Table 3. Resistance Proportion for Each Matrix-Species Combination During the 2004–2009 Test Perioda
Resistance (%) of Campylobacter coli from pork meat
2004d 2005d 2006d 2007d 2008d 2009d
Antimicrobial agent %Rb,c (n = 22) (n = 43) (n = 49) (n = 15) (n = 70) (n = 55)
Ampicillin 13.1 20.0 11.6 10.2 6.7 12.9 16.7
Ciprofloxacin 35.5 40.0 48.8 32.7 20.0 31.4 35.2
Erytromycin 17.9 25.0 18.6 12.2 6.7 21.4 18.5
Gentamycin 13.9 0,0 7.0 4.1 0.0 22.9 25.9
Nalidixic acid 35.5 40.0 48.8 32.7 20.0 31.4 35.2
Tetracycline 84.1 100.0 81.4 89.8 80.0 85.7 74.1
Resistance (%) of Campylobacter coli from poultry meat
2004d 2005d 2006d 2007d 2008d 2009d
Antimicrobial agent %Rb,c (n = 34) (n = 67) (n = 25) (n = 50) (n = 86) (n = 115)
Ampicillin 30.8 36.7 41.8 24.1 20.0 30.2 29.6
Ciprofloxacin 69.5 63.3 64.2 62.1 60.0 81.4 71.3
Erytromycin 13.0 13.3 6.0 6.9 8.0 14.0 20.0
Gentamycin 9.3 0.0 0.0 0.0 0.0 10.5 22.6
Nalidixic acid 69.8 60.0 67.2 58.6 60.0 86.0 68.7
Tetracycline 76.9 73.3 83.6 96.6 70.0 87.2 64.3
Resistance (%) of Campylobacter jejuni from poultry meat
2004d 2005d 2006d 2007d 2008d 2009d
Antimicrobial agent %Rb,c (n = 163) (n = 139) (n = 66) (n = 111) (n = 313) (n = 292)
Ampicillin 37.4 37.0 29.5 32.9 34.2 34.2 47.4
Ciprofloxacin 38.0 33.3 26.6 34.1 34.2 43.5 42.6
Erytromycin 6.0 1.2 2.2 1.2 0.0 8.0 12.1
Gentamycin 12.9 1.9 1.4 0.0 0.0 19.8 25.6
Nalidixic acid 39.5 34.0 27.3 30.5 34.2 45.7 46.4
Tetracycline 40.8 35.8 29.5 46.3 36.0 44.4 45.3
aResults from 2004–2009 were summated.
bEuropean Committee on Antimicrobial Susceptibility Testing epidemiological cut-off values were used to assign resistance.
cAverage %R.
dResistance (%) per year.
FIG. 2. Yearly trends in multiresistance per species-matrix combination. Multiresistance is defined as resistance to four or
more of the tested antibiotics.
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antimicrobials were observed (0.8% and 1%, respectively),
whereas none were found in pork. Pan-susceptibility was
significantly lower in C. coli (8% and 5% in pork and poultry,
respectively), compared to C. jejuni (29% in poultry).
Resistance to (fluoro)quinolones (like ciprofloxacin and
nalidixic acid) in Campylobacter spp. is mainly caused by
mutations in the DNA gyrase A gene (Payot et al., 2006).
Unlike in other Gram-negative bacteria, where high level
resistance is acquired by stepwise accumulation of point
mutations, a single mutation in the quinolone-resistance-
determining region (QRDR, C257T mutation) suffices to
confer resistance (Luo et al., 2003). For 97.5% of isolates, out of
a selection of 89 ciprofloxacin-resistant strains, the C257T
mutation was confirmed by mismatch amplification mutation
assay–PCR (MAMA-PCR). Only two ciprofloxacin-resistant
strains showed the wild-type gyrA gene with a cytosine at
position 257.
The most common mechanism for macrolide resistance
(like erythromycin) is target modification through point mu-
tations in the 23S rRNA genes (A2074C and/or A2075G), of
which there are three copies. MAMA-PCR showed the pres-
ence of the A2075G mutation in approximately 60% of the
selected erythromycin-resistant strains, while the A2074C
mutation was absent in all isolates. The sequence of the 23S
rRNA gene of the remaining 40% of erythromycin-resistant
strains was determined. All strains showed the wild-type
adenine at position 2074 and 2075, indicating that another
mechanism is responsible for the observed erythromycin re-
sistance. Both laboratory studies and surveillance programs
showed that fluoroquinolone resistance-conferring mutations
in the gyrA gene of Campylobacter spp. result in a fitness ad-
vantage (Luangtongkum et al., 2009). For instance, Luo et al.
(2005) observed that quinolone-resistant C. jejuni isolates re-
peatedly outcompeted susceptible strains in the gut of a
chicken animal model, demonstrating the positive effect of
resistance on the fitness of this strain. On the other hand,
resistance to macrolides are reported to cause a fitness bur-
den, resulting in macrolide-resistant strains that will be out-
competed by natural strains once antibiotic pressure
disappears (Caldwell et al., 2008). Regardless of the potential
biological relationship between virulence and antimicrobial
resistance in Campylobacter spp., the clinical evidence suggests
a bigger health burden due to infections caused by resistant
strains (Aarestrup et al., 2008).
Furthermore, Campylobacter spp. develop resistance to b-
lactam antimicrobials by expression of b-lactamases (chro-
mosomal OXA-type) and to tetracyclines through expression
of the ribosome conformational modifying protein Tet(O)
(Avrain et al., 2004). However, apart from these individ-
ual resistance mechanisms, the expression of the energy-
dependent multidrug efflux system CmeABC is known to be
widespread among Campylobacter spp. (Olah et al., 2006).
Studies have shown that CmeABC expression confers resis-
tance to fluoroquinolones, b-lactams, erythromycin, and tet-
racycline (with an increase of MIC by 8-, 32-, 4-, and 8-fold,
respectively) (Lin et al., 2002). The effect of CmeABC on
aminoglycoside resistance (like gentamicin) is less apparent
(Lin et al., 2002). The most common antimicrobial multi-
resistance profiles found in our monitoring program were
Amp-Cip-Nal-Tet and Cip-Nal-Ery-Tet, which are in agree-
ment with the reported effect of the CmeABC multidrug ef-
flux system.
Conclusion
Our study demonstrated an overall high antimicrobial re-
sistance in Campylobacter isolates from meat. A remarkable
increase of gentamicin resistance has been observed since
2007, which has thus far been unreported in poultry meat.
Significantly more fluoroquinolone resistance is observed in
meat from poultry compared to meat from pig, which is in
agreement with the more frequent use of these antimicrobials
in poultry husbandry. The C257T mutation of the gyrA gene
was confirmed for nearly all fluoroquinolone-resistant iso-
lates, whereas 40% of the erythromycin-resistant isolates in
both C. jejuni and C. coli have the wild-type 23S rRNA gene.
The high and increasing resistance proportions observed in
this study, especially in poultry, combined with the high
prevalence of Campylobacter in poultry carcasses at retail (25%,
Table 1) are worrisome.
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